As the diagnostics industry explores innovative ways to monitor and contain bacterial infections, Illumina is joining forces with French diagnostic outfit bioMérieux to develop a next-generation sequencing system that can identify infectious bacteria in service labs and hospitals.
Illumina is lending a hand to Ebola diagnostic efforts, teaming up with U.S. government officials and researchers at the Broad Institute to help scientists in West Africa track the virus and develop new tools to prevent its spread.
Amid growing efforts to quell the deadly Ebola outbreak, diagnostic giant Illumina is teaming up with U.S. government officials and Broad Institute researchers to help scientists in West Africa track the virus in real time and develop new tools to prevent its spread.
Coming off a huge third quarter for revenue growth, genomic sequencing outfit Illumina this week inked a deal with Sequenta to commercialize a diagnostics kit that detects a condition associated with cancer remission.
Genomic sequencing seems to have come of age with Illumina as a substantial driver and beneficiary. During the third quarter, the company achieved astonishing revenue growth of 35% to $481 million over the same quarter last year.
Genomics England has dropped two-thirds of the candidates to provide variant annotation and clinical interpretation services to the 100,000 Genomes Project after reviewing the first round of responses.
Preimplantation genetic screening and diagnostics provider Reprogenetics is partnering with Illumina to use its next-generation sequencing tech in its analysis of embryos and infertility.
Illumina has teamed up with AB Sciex to add proteomic data analysis capabilities to its BaseSpace platform. As a result of the collaboration, Illumina is hosting four apps for processing, analyzing and visualizing proteomics mass spectrometry data on BaseSpace.
Global CRO Quintiles and gene sequencing magnate Illumina are scouting for some promising scientists, offering the use of their cash and technology to advance oncology research.
Illumina has laid the groundwork for increased use of next-generation sequencing in clinical research by striking a deal with Big Pharma, which could result in the company disrupting diagnostics using its dominance in NGS.